Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 6, 2007, Pages 743-747

  Berg, Stacey L ^a   Brueckner, Claudia ^b   Nuchtern, Jed G ^c   Dauser, Robert ^c   McGuffey, Leticia ^a   Blaney, Susan M ^a  

^a TEXAS CHILDREN S CANCER CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GUANINE ARABINOSIDE; NELARABINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CANCER PREVENTION; CENTRAL NERVOUS SYSTEM TUMOR; CENTRAL VENOUS CATHETER; CEREBROSPINAL FLUID ANALYSIS; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEUKEMIA; MALE; MASS SPECTROMETRY; NONHUMAN; PREDICTION; PRIMATE; PRIORITY JOURNAL; TREATMENT INDICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MACACA MULATTA; MALE; MASS SPECTROMETRY; PRODRUGS;

EID: 33947326086     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0328-0     Document Type: Article

References (17)

1. Blaney S, Poplack D (2000) Neoplastic meningitis: diagnosis and treatment considerations. Med Oncol 17:151-162
2. Kerr JZ, Berg S, Blaney SM (2001) Intrathecal chemotherapy. Crit Rev Oncol Hematol 37(3):227-236
3. Donehower R, Karp J, Burke P (1986) Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 70:1059-1065
4. Slevin M, Piall E, Aherne G, Harvey V, Johnston A, Lister T (1983) Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1:546-551
5. Kearns CM, Blakley RL, Santana VM, Crom WR (1994) Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res 54(5):1235-1239
6. Berg S, Bonate P, Nuchtern J et al (2005) Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res 11:5981-5983
7. Lambe C, Averett D, Paff M, Reardon J, Wilson J, Krenitsky T (1995) 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res 55:3352-3356
8. Kurtzberg J, Ernst TJ, Keating MJ et al (2005) Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23(15):3396-403
9. Berg SL, Blaney SM, Devidas M et al (2005) Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 23(15):3376-3382
10. Nelarabine Investigator's Brochure (1996) GloxoSmithKline
11. McCully C, Balis F, Bacher J, Phillips J, Poplack D (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Animal Sci 40:522-525
12. National Research Council (1996) Guide for the care and use of laboratory animals. National Academy Press, Washington
13. Gibaldi M, Perrier D (1982) Pharmacokinetics. 2nd edn. Marcel Dekker Inc, New York and Basel
14. D'Argenio D, Schumitzky A (1997) ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. biomedical simulations resource, University of Southern California, Los Angeles
15. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175
16. Kisor DF, Plunkett W, Kurtzberg J et al (2000) Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 18(5):995-1003
17. Shewach D, Mitchell B (1989) Differential metabolism of 9-b-D-arabinofuranosylguanine in human leukemic cells. Cancer Res 49:6498-6502